VM4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Fanapt Commercial Momentum And Sales Force ExpansionSustained prescription growth and a larger sales force (300 reps) indicate durable commercial traction. Higher TRx/NBRx and rep coverage improve prescribing habits and payer adoption over time, supporting a stable revenue base and scaling operating leverage as volume grows.
Regulatory Approvals And Late‑stage Pipeline ProgressAn approved new branded product (Dysanti) with multi‑year exclusivity and a late‑stage asset (imsidolimab) nearing regulatory action materially diversifies and lengthens revenue potential. These structural milestones reduce binary pipeline risk and create multi‑year commercial runway if approvals convert to sales.
Low Leverage And Balance Sheet FlexibilityLow debt levels reduce refinancing and interest risks, granting strategic optionality to fund launches, marketing and trials without immediate liquidity stress. This structural strength supports multi‑quarter operational flexibility despite temporary cash burn from launches.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained negative OCF and FCF force reliance on cash reserves or external financing to fund operations and pipeline steps. Over several quarters this increases dilution or covenant risk, constrains discretionary investment, and narrows strategic options for commercial scale‑up.
Large Operating And Net Losses Eroding ProfitabilityDespite top‑line growth, persistent operating and net losses reduce retained capital and hinder return generation. Continued losses erode equity, increase financing needs, and make long‑term margin recovery essential before the business can sustainably self‑fund growth.
Hetlioz Revenue Erosion From Generic CompetitionLoss of a legacy product to generics materially reduces predictable cash flow and increases dependency on newer launches. Structural erosion of an established franchise raises sustainability risk for margins and heightens pressure to replace lost revenue with successful launches or approvals.
Vanda News
VM4 FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Currently, no data Available
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is CHF252.90M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported -CHF0.668 earnings per share for the quarter, missing the consensus estimate of -CHF0.561 by -CHF0.108.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.47.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Currently, no data Available
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -CHF0.668 in its last earnings report, missing expectations of -CHF0.561. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CH:VM4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF15.29 (― Upside)
CHF15.29 (― Upside)
Blogger Sentiment
Bullish
CH:VM4 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.40%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VM4 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and pipeline momentum story: Fanapt demonstrated strong prescription growth and the company launched Nirius via a novel direct‑to‑consumer model while securing FDA approval for Dysanti and advancing imsidolimab toward potential year‑end regulatory action. Management raised 2026 revenue guidance and outlined multiple upcoming Phase 3 readouts that could be value drivers. Offsetting these positives are a materially larger Q1 net loss, increased operating expenses, a significant cash decline and ongoing Hetlioz erosion from generics, plus some development and recruitment risks for certain programs. Overall, commercial and regulatory catalysts appear to outweigh near‑term financial pressures.View all CH:VM4 earnings summariesVM4 Stock 12 Month Forecast
Average Price Target
―Omeros
―
Aldeyra Therapeutics
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Alector
―